menu
    • menu
    [{"orgOrder":0,"company":"Vasa Therapeutics","sponsor":"NuFund Venture Group","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vasa Therapeutics Announces Closing of Seed Financing to Advance Novel Therapies for Diseases of Cardiovascular Aging","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"VS-041","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Vasa Therapeutics","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Vasa Therapeutics \/ NuFund Venture Group","highestDevelopmentStatusID":"5","companyTruncated":"Vasa Therapeutics \/ NuFund Venture Group"}]

    Find Clinical Drug Pipeline Developments & Deals by Vasa Therapeutics

    Menu

    Vasa Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vasa Therapeutics

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Vasa Therapeutics

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VS-041

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : IND Enabling

                            Sponsor : NuFund Venture Group

                            Deal Size : $6.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Vasa Therapeutics Announces Closing of Seed Financing to Advance Novel Therapies for Diseases of Cardiovascula...

                            Details : The net proceeds will be used to advance novel therapies for cardiovascular aging, including VS-041, the first potential personalized medicine-based treatment of heart failure with preserved ejection fraction (HFpEF).

                            Brand Name : VS-041

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 03, 2024

                            Lead Product(s) : VS-041

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : NuFund Venture Group

                            Deal Size : $6.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth